Proteomics

Dataset Information

0

Targeting UGCG overcomes resistance to lysosomal autophagy inhibition


ABSTRACT: Lysosomal autophagy inhibition (LAI) with hydroxychloroquine or DC661 can enhance cancer therapy, but tumor regrowth is common. To elucidate LAI resistance, proteomics and immunoblotting demonstrated that LAI induced lipid metabolism enzymes in multiple cancer cell lines. Lipidomics showed that LAI increased cholesterol, sphingolipids, and glycosphingolipids. These changes were associated with striking levels of GM1+ membrane microdomains (GMM) in plasma membranes and lysosomes. Inhibition of cholesterol/sphingolipid metabolism proteins enhanced LAI cytotoxicity. Targeting UDP-glucose ceramide glucosyltransferase (UGCG) synergistically augmented LAI cytotoxicity. While UGCG inhibition decreased LAI-induced GMM and augmented cell death, UGCG overexpression led to LAI resistance. Melanoma patients with high UGCG expression had significantly shorter disease-specific survival. The FDA-approved UGCG inhibitor eliglustat combined with LAI significantly inhibited tumor growth and improved survival in syngeneic tumors and a therapy-resistant patient-derived xenograft. These findings nominate UGCG as a new cancer target, and clinical trials testing UGCG inhibition in combination with LAI are warranted.

INSTRUMENT(S): Q Exactive Plus

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Ravi Amaravadi  

PROVIDER: MSV000089020 | MassIVE | Tue Mar 08 06:46:00 GMT 2022

SECONDARY ACCESSION(S): PXD032120

REPOSITORIES: MassIVE

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2022-03-08 | MSV000089020 | GNPS
2021-05-11 | PXD021877 | Pride
2018-11-24 | GSE122860 | GEO
2008-09-17 | E-TABM-450 | biostudies-arrayexpress
2024-08-01 | GSE271926 | GEO
2015-11-09 | E-GEOD-69042 | biostudies-arrayexpress
2019-07-02 | PXD011222 | Pride
2017-02-14 | GSE93193 | GEO
2008-06-15 | E-GEOD-6652 | biostudies-arrayexpress
2020-04-04 | GSE132055 | GEO